Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation
Experimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation. However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2018/7209872 |
id |
doaj-db33585399b84f2aa3c28464ea5bc3a6 |
---|---|
record_format |
Article |
spelling |
doaj-db33585399b84f2aa3c28464ea5bc3a62020-11-25T01:41:18ZengHindawi LimitedJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/72098727209872Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic InflammationCamilo P. Martínez-Reyes0Angélica Y. Gómez-Arauz1Israel Torres-Castro2Aarón N. Manjarrez-Reyna3León F. Palomera4Alfonso Olivos-García5Edith Mendoza-Tenorio6Gabriela A. Sánchez-Medina7Sergio Islas-Andrade8Guillermo Melendez-Mier9Galileo Escobedo10Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoUnit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoUnit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoUnit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoUnit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoDepartamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 México, DF, MexicoDepartamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 México, DF, MexicoResearch Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoResearch Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoResearch Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoUnit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, MexicoExperimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation. However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are still unknown. Our main goal was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with anthropometric, metabolic, and low-grade systemic inflammatory markers. Ninety-two participants were included in the study and divided into insulin-resistant patients and noninsulin-resistant controls. Blood levels of IL-13, glucose, insulin, triglycerides, cholesterol, tumor necrosis factor-alpha (TNF-α), IL-10, proinflammatory (Mon-CD11c+CD206−), and anti-inflammatory (Mon-CD11c−CD206+) monocytes, as well as anthropometric parameters, were measured in all volunteers. Insulin-resistant patients showed 2.5-fold higher serum levels of IL-13 than controls (P<0.0001) and significantly increased values of TNF-α and Mon-CD11c+CD206−, with concomitant reductions in IL-10 and Mon-CD11c−CD206+. Increased IL-13 was extraordinarily well associated with hyperglycemia (r=0.7362) and hypertriglyceridemia (r=0.7632) but unexpectedly exhibited no significant correlations with TNF-α (r=0.2907), IL-10 (r=−0.3882), Mon-CD11c+CD206− (r=0.2745) or Mon-CD11c−CD206+ (r=−0.3237). This study demonstrates that IL-13 serum levels are elevated in patients with insulin resistance without showing correlation with parameters of low-grade systemic inflammation.http://dx.doi.org/10.1155/2018/7209872 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Camilo P. Martínez-Reyes Angélica Y. Gómez-Arauz Israel Torres-Castro Aarón N. Manjarrez-Reyna León F. Palomera Alfonso Olivos-García Edith Mendoza-Tenorio Gabriela A. Sánchez-Medina Sergio Islas-Andrade Guillermo Melendez-Mier Galileo Escobedo |
spellingShingle |
Camilo P. Martínez-Reyes Angélica Y. Gómez-Arauz Israel Torres-Castro Aarón N. Manjarrez-Reyna León F. Palomera Alfonso Olivos-García Edith Mendoza-Tenorio Gabriela A. Sánchez-Medina Sergio Islas-Andrade Guillermo Melendez-Mier Galileo Escobedo Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation Journal of Diabetes Research |
author_facet |
Camilo P. Martínez-Reyes Angélica Y. Gómez-Arauz Israel Torres-Castro Aarón N. Manjarrez-Reyna León F. Palomera Alfonso Olivos-García Edith Mendoza-Tenorio Gabriela A. Sánchez-Medina Sergio Islas-Andrade Guillermo Melendez-Mier Galileo Escobedo |
author_sort |
Camilo P. Martínez-Reyes |
title |
Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation |
title_short |
Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation |
title_full |
Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation |
title_fullStr |
Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation |
title_full_unstemmed |
Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation |
title_sort |
serum levels of interleukin-13 increase in subjects with insulin resistance but do not correlate with markers of low-grade systemic inflammation |
publisher |
Hindawi Limited |
series |
Journal of Diabetes Research |
issn |
2314-6745 2314-6753 |
publishDate |
2018-01-01 |
description |
Experimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation. However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are still unknown. Our main goal was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with anthropometric, metabolic, and low-grade systemic inflammatory markers. Ninety-two participants were included in the study and divided into insulin-resistant patients and noninsulin-resistant controls. Blood levels of IL-13, glucose, insulin, triglycerides, cholesterol, tumor necrosis factor-alpha (TNF-α), IL-10, proinflammatory (Mon-CD11c+CD206−), and anti-inflammatory (Mon-CD11c−CD206+) monocytes, as well as anthropometric parameters, were measured in all volunteers. Insulin-resistant patients showed 2.5-fold higher serum levels of IL-13 than controls (P<0.0001) and significantly increased values of TNF-α and Mon-CD11c+CD206−, with concomitant reductions in IL-10 and Mon-CD11c−CD206+. Increased IL-13 was extraordinarily well associated with hyperglycemia (r=0.7362) and hypertriglyceridemia (r=0.7632) but unexpectedly exhibited no significant correlations with TNF-α (r=0.2907), IL-10 (r=−0.3882), Mon-CD11c+CD206− (r=0.2745) or Mon-CD11c−CD206+ (r=−0.3237). This study demonstrates that IL-13 serum levels are elevated in patients with insulin resistance without showing correlation with parameters of low-grade systemic inflammation. |
url |
http://dx.doi.org/10.1155/2018/7209872 |
work_keys_str_mv |
AT camilopmartinezreyes serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT angelicaygomezarauz serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT israeltorrescastro serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT aaronnmanjarrezreyna serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT leonfpalomera serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT alfonsoolivosgarcia serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT edithmendozatenorio serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT gabrielaasanchezmedina serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT sergioislasandrade serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT guillermomelendezmier serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation AT galileoescobedo serumlevelsofinterleukin13increaseinsubjectswithinsulinresistancebutdonotcorrelatewithmarkersoflowgradesystemicinflammation |
_version_ |
1725041566061428736 |